Bosentan and Overcirculation-Induced Experimental Pulmonary Arterial Hypertension

To the Editor:

In the article by Rondelet et al.,1 the authors report data obtained from a model of increased pulmonary blood flow induced by a left-to-right shunt after creation of an anastomosis between the left subclavian artery and the pulmonary artery (Blalock-Taussig shunt) in piglets aged 20±1 days and weighing 5.9±0.2 kg. After an observation period of 90±1 days, the animals underwent reinstitution for hemodynamic evaluation.

With respect to the hemodynamic data as given in Table 2 of their paper,1 the mean systemic arterial pressure was reported to be 131 to 133 mm Hg in the 3 groups of farm piglets studied under general anesthesia. This implicates an unusually high systemic arterial pressure in their animals; other groups2–4 have reported the mean systemic arterial blood pressure to be ∼87 mm Hg (range, 60 to 103 mm Hg, depending on the anesthetic regime used), which is similar to our own findings.5 Especially in the group treated with bosentan, a substance known to lower both pulmonary and systemic arterial blood pressure, one would expect a lower mean systemic blood pressure compared with a sham or placebo group. But this was not the case in the series of Rondelet and coworkers.1 Taking into account that the increase in pulmonary artery pressure achieved by the Blalock-Taussig anastomosis was small in relation to the high systemic arterial blood pressure, the model presented by Rondelet’s group reflects pulmonary vascular disease induced by high pulmonary blood flow without an important elevation in pulmonary artery pressure.

Michael V. Ullmann, MD
Department of Cardiac Surgery
University of Heidelberg
Heidelberg, Germany

Matthias Gorenflo, MD
Department of Pediatric Cardiology
University of Heidelberg
Heidelberg, Germany

Response

Ullmann and colleagues criticize our paper on overcirculation-induced pulmonary arterial hypertension in piglets1 on the basis of an excessively high systemic arterial pressure, an absence of significant systemic vasodilating effects of bosentan, and only a moderate increase in pulmonary artery pressure.

The porcine blood pressure has been reported variably in the literature, depending on strain, cardiac output, and anesthetic regimen. Many investigators also measured relatively high mean systemic arterial pressures, in the range of 111 to 135 mm Hg.2–4 It is likely that blood pressure is normally higher in pigs than in many other species, including humans.

The absence of a decrease in blood pressure under chronic bosentan therapy has also been noted in patients with pulmonary arterial hypertension,5 indicating a more important role for endothelin in abnormally increased pulmonary vascular resistance than in the maintenance of normal systemic hemodynamics.

As for the pulmonary hemodynamic measurements, it must be emphasized that pulmonary artery pressure was measured after closure of the Blalock-Taussig anastomosis and control of venous return to correct for any flow-related component of induced pulmonary hypertension. Under these conditions, pulmonary vascular resistance increased by 57% as a result of an 80% increase in medial thickness of resistive arterioles. Mean pulmonary artery pressure increased to 33 mm Hg. This is admittedly lower than in patients with pulmonary arterial hypertension, who present with mean pulmonary artery pressures of ∼50 mm Hg.5 However, the change was highly significant and was compatible with relatively early stages of the disease, which is exactly what we wanted to study.1

Benoit Rondelet, MD
François Kerbaul, MD
Sophie Motte, DVM
Serge Brimiouille, MD, PhD
Kathleen McEntee, DVM, PhD
Pierre Wauthy, MD
Robert Naëije, MD, PhD
Laboratory of Physiology
Free University of Brussels
Brussels, Belgium

Ronald van Beneden, MSc
Jean-Marie Keteslegers, MD, PhD
Unit of Diabetes and Nutrition
Catholic University of Louvain
Brussels, Belgium

Myriam Remmelink, MD, PhD
Isabelle Salmon, MD, PhD
Department of Pathology
Erasmus University Hospital
Brussels, Belgium


Bosentan and Overcirculation-Induced Experimental Pulmonary Arterial Hypertension
Michael V. Ullmann and Matthias Gorenflo

_Circulation_. 2003;108:e157
doi: 10.1161/01.CIR.0000102941.83506.6E
_Circulation_ is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2003 American Heart Association, Inc. All rights reserved.
Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://circ.ahajournals.org/content/108/23/e157

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in _Circulation_ can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to _Circulation_ is online at:
http://circ.ahajournals.org//subscriptions/